Business Description
Harpoon Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
5HT.GermanyHARP.USA Description
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.02 | |||||
| Equity-to-Asset | 0.2 | |||||
| Debt-to-Equity | 0.65 | |||||
| Debt-to-EBITDA | -0.16 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -7.49 | |||||
| Beneish M-Score | -1.9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 54.4 | |||||
| 3-Year EBITDA Growth Rate | -20.9 | |||||
| 3-Year EPS without NRI Growth Rate | 43.2 | |||||
| 3-Year FCF Growth Rate | -48.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.55 | |||||
| 9-Day RSI | 61.32 | |||||
| 14-Day RSI | 59.89 | |||||
| 6-1 Month Momentum % | -62.78 | |||||
| 12-1 Month Momentum % | -85.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.28 | |||||
| Cash Ratio | 1.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -11.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -221.31 | |||||
| Net Margin % | -220.41 | |||||
| ROE % | -161.07 | |||||
| ROA % | -54.09 | |||||
| ROIC % | -130.56 | |||||
| ROC (Joel Greenblatt) % | -490.17 | |||||
| ROCE % | -96.25 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 1.12 | |||||
| PB Ratio | 2.12 | |||||
| Price-to-Tangible-Book | 2.12 | |||||
| EV-to-EBIT | 0.29 | |||||
| EV-to-EBITDA | 0.3 | |||||
| EV-to-Revenue | -0.64 | |||||
| EV-to-Forward-Revenue | 0.8 | |||||
| EV-to-FCF | 0.24 | |||||
| Price-to-Net-Current-Asset-Value | 13.5 | |||||
| Earnings Yield (Greenblatt) % | 344.83 |
